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ORIGINAL ARTICLE
Clinical Conditions and Their Impact on Utility of 
Genetic Scores for Prediction of Acute Coronary 
Syndrome
Jiwoo Lee , MS; Tuomo Kiiskinen, MD; Nina Mars , MD; Sakari Jukarainen , MD; Erik Ingelsson , MD, PhD;  
Benjamin Neale, PhD; Samuli Ripatti , PhD; Pradeep Natarajan , MD, MMSc; Andrea Ganna , PhD
BACKGROUND: Acute coronary syndrome (ACS) is a clinically significant presentation of coronary heart disease. Genetic 
information has been proposed to improve prediction beyond well-established clinical risk factors. While polygenic scores 
(PS) can capture an individual’s genetic risk for ACS, its prediction performance may vary in the context of diverse correlated 
clinical conditions. Here, we aimed to test whether clinical conditions impact the association between PS and ACS.
METHODS: We explored the association between 405 clinical conditions diagnosed before baseline and 9080 incident cases 
of ACS in 387 832 individuals from the UK Biobank. Results were replicated in 6430 incident cases of ACS in 177 876 
individuals from FinnGen.
RESULTS: We identified 80 conventional (eg, stable angina pectoris and type 2 diabetes) and unconventional (eg, 
diaphragmatic hernia and inguinal hernia) associations with ACS. The association between PS and ACS was consistent in 
individuals with and without most clinical conditions. However, a diagnosis of stable angina pectoris yielded a differential 
association between PS and ACS. PS was associated with a significantly reduced (interaction P=2.87×10−8) risk for 
ACS in individuals with stable angina pectoris (hazard ratio, 1.163 [95% CI, 1.082–1.251]) compared with individuals 
without stable angina pectoris (hazard ratio, 1.531 [95% CI, 1.497–1.565]). These findings were replicated in FinnGen 
(interaction P=1.38×10−6).
CONCLUSIONS: In summary, while most clinical conditions did not impact utility of PS for prediction of ACS, we found that 
PS was substantially less predictive of ACS in individuals with prevalent stable coronary heart disease. PS may be more 
appropriate for prediction of ACS in asymptomatic individuals than symptomatic individuals with clinical suspicion for coronary 
heart disease.
Key Words: acute coronary syndrome ◼ diagnosis ◼ genetics ◼ heart diseases
Acute coronary syndrome (ACS), including myocardial infarction, is an unstable consequence of coronary heart disease (CHD), the leading cause of death 
worldwide. In Europe, CHD accounts for 1.8 million 
deaths per year, making up almost 20% of all cardiovas-
cular disease-related deaths.1 Thus, prediction of ACS 
and prevention of CHD remain major public health issues.
Well-established clinical risk factors, such as type 
2 diabetes and hypercholesterolemia, are highly pre-
dictive of future health outcomes, including ACS.2,3 
Individuals with an accumulation of such risk factors 
are candidates for preventative statin interventions per 
American and European guidelines.2–4 Recently, other 
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ACS have been proposed to improve prediction of 
ACS and inform statin intervention decisions.5–8 Sev-
eral studies have effectively used machine learning 
approaches to leverage electronic health records for 
prediction of cardiovascular diseases,6,9–15 and unbi-
ased, comprehensive analyses of diverse correlated 
clinical conditions in large-scale biobanks may con-
tinue to better inform prediction of ACS.
Furthermore, genetic information may inform pre-
diction of ACS beyond well-established clinical risk 
factors.16–20 Currently, guidelines on evaluating risk 
for ACS and initiating statin interventions rely on 
several well-established clinical risk factors but do 
not support the use of genetic information. However, 
genetic information has the advantage of remaining 
stable throughout life and, therefore, could be used 
to improve earlier prediction of ACS.21–23 Results from 
large genome-wide association studies can be used 
to derive polygenic scores (PS) based on millions of 
single nucleotide polymorphisms that are robustly 
associated with CHD.24 Several studies have investi-
gated the use of PS for prediction of ACS in addition 
to well-established clinical risk factors.20,25–27 However, 
there are no studies to date that examine the associa-
tion between PS and ACS in the context of diverse 
correlated clinical conditions.
In this study, we have 2 main goals that we assessed 
in 2 large-scale biobanks. First, we aimed to compre-
hensively explore the association of clinical conditions 
with ACS. Second, we aimed to assess whether clinical 
conditions associated with ACS impact the association 
between PS and ACS to provide context for the use of 
PS for prediction of ACS.
METHODS
Full methods are available in the Data Supplement. Because 
of the sensitive nature of the data collected for this study, 
requests to access the data set from qualified researchers 
trained in human subject confidentiality protocols may be 
sent to the UK Biobank or FinnGen at access@ukbiobank.
ac.uk or finngen-info@helsinki.fi, respectively. This study was 
approved by an institutional review committee, and subjects 
gave informed consent.
RESULTS
Several Clinical Conditions Are Associated With 
ACS
In the UK Biobank, we explored the association between 
405 clinical conditions diagnosed before baseline and 
9080 cases of ACS out of 387 832 individuals (Table; 
exclusion criteria in Table I in the Data Supplement) 
and identified 80 clinical conditions that were signifi-
cantly (P<1.23×10−4) associated with ACS after mul-
tiple testing correction (Figure 1). The 80 associated 
clinical conditions had an average hazard ratio of 2.4 
for ACS. Some of these associations were conventional 
(eg, stable angina pectoris [SAP] and type 2 diabetes), 
and others were unconventional (eg, diaphragmatic her-
nia and inguinal hernia). Adjustment for measured risk 
factors modestly reduced the association, but statistical 
significance was retained for all 80 clinical conditions. 
Table II in the Data Supplement includes all 80 clinical 
conditions that were associated with ACS before and 
after adjustment for measured risk factors. This analy-
sis was replicated in FinnGen, in which we explored the 
association between 645 clinical conditions and 6430 
cases of ACS out of 177 876 individuals (Table; exclu-
sion criteria in Table I in the Data Supplement) and 
identified 71 clinical conditions that were significantly 
(P<7.75×10−5) associated with ACS after multiple test-
ing correction (Figure I in the Data Supplement). The 
71 associated clinical conditions had an average hazard 
ratio of 2.1 for ACS. Table III in the Data Supplement 
includes all 71 clinical conditions that were associated 
with ACS. Thirty-three clinical conditions were associ-
ated with ACS in both the UK Biobank and FinnGen. For 
these clinical conditions, we observed good consistency 
(R2=0.65) between the association observed in the UK 
Biobank and FinnGen, suggesting the generalizability of 
these associations across 2 large-scale biobanks (Fig-
ure II in the Data Supplement).
Most Clinical Conditions Do Not Impact 
Association Between PS and ACS Except for 
SAP
First, we confirmed that PS was associated with ACS 
in the UK Biobank (HR for 1 SD increase in PS=1.49 
[95% CI, 1.46–1.53], P=1.36×10−294) and FinnGen 
(HR for 1 SD increase in PS=1.44 [95% CI, 1.40–1.47], 
P=1.71×10−166). Next, we aimed to understand the 
value of measuring PS in individuals without ACS at 
baseline and whether the association between PS and 
ACS changed given the diagnosis of certain clinical con-
ditions. We tested for the interaction between PS and 
80 clinical conditions that were associated with ACS in 
the UK Biobank and identified a significant interaction 
(P=2.87×10−8) between SAP and PS (Figure 2). Here, 
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
BMI body mass index
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SAP was defined as angina pectoris with documented 
spasm, other forms of angina pectoris, and unspecified 
angina pectoris (International Classification of Disease, 
Tenth Revision codes I20.1, I20.8, and I20.9). This was 
the only interaction (P=1.38×10−6) that was replicated 
in FinnGen (Figure III in the Data Supplement). In the 
UK Biobank, there were 5477 cases of SAP (preva-
lence=1.41%), and in FinnGen, there were 8326 cases 
of SAP (prevalence=4.68%). There was also a sig-
nificant interaction between PS and type 2 diabetes 
(P=6.01×10−6) in the UK Biobank, but this interaction 
was not significant after multiple testing correction in 
FinnGen (P=5.00×10−2).
In the UK Biobank, individuals with SAP had a sig-
nificantly reduced risk for ACS (HR for 1 SD=1.163 
[95% CI, 1.082–1.251]) compared with individuals 
without SAP (HR for 1 SD=1.531 [95% CI, 1.497–
1.565]; Figure 3). All individuals, with or without SAP, 
did not have ACS at baseline, as individuals with ACS 
at baseline were excluded from the analysis. In a model 
including measured risk factors in the UK Biobank, 
results remained consistent (SAP HR=1.159 [95% 
CI, 1.078–1.246] and no SAP HR=1.488 [95% CI, 
1.455–1.522], interaction P=2.05×10−7). This obser-
vation was replicated in FinnGen, and individuals with 
SAP had a significantly reduced risk for ACS (HR for 
1 SD=1.247 [95% CI, 1.173–1.326]) compared with 
individuals without SAP (HR for 1 SD=1.448 [95% CI, 
1.407–1.490]). PS was also strongly associated with 
SAP in the UK Biobank (HR, 1.44 [95% CI, 1.40–1.48], 
P=3.66×10−148) and FinnGen (HR, 1.47 [95% CI, 1.42–
1.49], P=1.32×10−228). Importantly, PS was also strongly 
associated with SAP in individuals who did not develop 
ACS in the UK Biobank (HR, 1.45 [95% CI, 1.41–1.48], 
P=4.45×10−112) and FinnGen (HR, 1.44 [95% CI, 1.40–
1.48], P=6.05×10−190), suggesting that there is a large 
overlap in the genetic basis of SAP and ACS.
We also noticed that the association between mea-
sured risk factors and ACS was generally weaker among 
individuals with SAP than individuals without SAP (Table 
IV in the Data Supplement). For example, there was no 
association between total cholesterol and ACS in individ-
uals with SAP (HR, 0.96 [95% CI, 0.89–1.03], P=0.247), 
but there was an association in individuals without SAP 
(HR, 1.11 [95% CI, 1.09–1.13], P=6.43×10−28).
Sensitivity Analyses
We performed several sensitivity analyses. First, because 
PS has been shown to have age-dependent effects25 
and individuals with SAP tended to be older and include 
more males than individuals without SAP, we performed 
an age- and sex-matched analysis to test whether differ-
ences in age or sex explained the differential association 
of PS and ACS. After matching age and sex distribu-
tions in individuals with and without SAP, the interaction 
between SAP and PS remained significant in both the UK 
Biobank (P=1.51×10−3) and FinnGen (P=1.16×10−2). 
We also adjusted our analysis for diabetes, and the inter-
action between SAP and PS remained significant in both 
the UK Biobank (interaction P=1.07×10−10) and Finn-
Gen (interaction P=3.77×10−4).
Second, because many well-established guidelines 
suggest statin interventions for individuals with SAP, we 
adjusted our analysis for statin use to explore whether 
statin use in individuals with SAP lowered the associa-
tion with ACS. Statin use in the UK Biobank was self-
reported, and statin use in FinnGen was defined using 
high-quality prescription registries. In the UK Biobank, 
82.1% of individuals with SAP used statins and 15.9% 
of individuals without SAP used statins. In FinnGen, 
81.7% of individuals with SAP used statins and 27.8% 
of individuals without SAP used statins. The interaction 
between SAP and PS remained significant after adjust-
ing for statin use in both the UK Biobank (P=1.20×10−10) 
and FinnGen (P=3.77×10−4). In the UK Biobank, the 
interaction between SAP and PS remained significant 
(P=7.39×10−4) after removing statin users. In FinnGen, 
the interaction between SAP and PS remained significant 
(P=3.85×10−4) after adjusting for additional prescrip-
tions, including statins, aspirins (ATC code B01AC06), all 
β-blockers (ATC code C07AB), and all angiotensin-con-
verting enzyme inhibitors (ATC code C09AA). However, 
given the high prevalence of prescription usage in this 
patient population compared to the general population, 
we cannot eliminate the possibility of an additive effect 
from additional prescriptions that were not considered in 
this analysis.
Third, we increased the time window between a diag-
nosis of SAP and an ACS event to reduce the chances 
Table. Summary of Baseline Characteristics of Cohorts 
From UK Biobank and FinnGen
 UK Biobank FinnGen
No. of individuals without ACS 
at baseline
387 832 177 876
No. of ACS cases (%) 9080 (2.34) 6430 (3.61)
No. of SAP cases (%) 5477 (1.41) 8326 (4.68)
Average follow-up time, y (SD) 11.97 (1.36) 7.18 (8.29)
Average age, y (SD) 56.47 (8.09) 51.29 (17.33)
No. of females (%) 210 340 (54.23) 100 929 (56.74)
No. of statin users (%) 65 419 (16.87) 53 886 (30.29)
No. of smokers (%) 174 763 (45.06) …
Average body mass index,  
kg/m2 (SD)
27.38 (4.75) …
Average systolic blood pressure, 
mm Hg (SD)
139.8 (19.64) …
Average high-density lipoprotein 
cholesterol, mmol/L (SD)
1.45 (0.38) …
Average total cholesterol, 
mmol/L (SD)
5.71 (1.13) …
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of capturing the same underlying cardiovascular event. 
Increasing the time window from 30 days to 300 and 
500 days only modestly reduced the interaction between 
SAP and PS in the UK Biobank (300 days P=5.14×10−11 
and 500 days P=3.76×10−11) and FinnGen (300 days 
P=5.83×10−4 and 500 days P=1.86×10−3). Average 
and median time between an SAP diagnosis and an ACS 
event was 9.1 and 8.9 years, respectively, in the UK Bio-
bank. Similarly, average and median time was 6.7 and 
5.7 years, respectively, in FinnGen. This suggested that 
the cases of SAP captured in our study were diagnosed 
earlier and independent of the events of ACS.
Fourth, we examined the interaction between SAP and 
ACS in different ancestry groups. Our cohort from the 
UK Biobank included individuals of African (n=5543), 
Ad Mixed American (n=820), Central and South Asian 
(n=6976), East Asian (n=2196), European (n=339 771), 
and Middle Eastern (n=1258) ancestry. In Central and 
South Asian (ACS cases=306, SAP diagnoses=194, 
P=1.14×10−2) and European (ACS cases=7969, SAP 
diagnoses=4810, P=2.36×10−11), the interaction between 
SAP and PS remained significant. Other ancestry groups, 
which included <100 diagnoses of SAP and 100 cases of 
ACS, were not analyzed due to the lack of statistical power.
Figure 1. Association between 405 
clinical conditions and 9080 cases of 
acute coronary syndrome unadjusted 
and adjusted for measured risk 
factors from the UK Biobank.
We used time-varying covariate Cox 
survival models (A), and adjusted for 
age, sex, and principal components (B). 
Measured risk factors included body 
mass index, systolic blood pressure, 
smoking status, high-density lipoprotein 
cholesterol, and total cholesterol. Red 
dotted line is the significance threshold 
after multiple testing correction 
(P<1.23×10−4). Top 10 clinical conditions 
are labeled.Dow
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Fifth, we considered the possibility that the significant 
interaction between SAP and PS was simply capturing 
underlying differences in risk factor distribution between 
individuals with and without SAP. If this was the case, 
we would observe significant interactions between PS 
and cardiovascular risk factors. We tested for the inter-
action between PS and body mass index (BMI), systolic 
blood pressure, smoking status, HDL (high-density lipo-
protein) cholesterol, and total cholesterol. There were 
no significant interactions between PS and measured 
risk factors, except for BMI (interaction P=8.30×10−3). 
However, the effect size change was minimal for the 
interaction between BMI and PS (SAP HR=1.031 [95% 
CI, 1.017–1.045]; no SAP HR=1.047 [95% CI, 0.9979–
1.008]) compared with the interaction between SAP and 
PS (SAP HR=1.163 [95% CI, 1.082–1.251]; no SAP 
HR=1.531 [95% CI, 1.497–1.565]).
Prediction Performance of PS Differs Between 
Individuals With and Without SAP
We examined the Harrell C index to evaluate the predic-
tion performance of PS (Figure 4). In the UK Biobank, 
individuals with SAP had a C index for PS of 0.606 (95% 
CI, 0.595–0.616) and individuals without SAP had a C 
index for PS of 0.747 (95% CI, 0.743–0.750) in models 
adjusted for age, sex, principal components, BMI, systolic 
blood pressure, smoking status, HDL cholesterol, and 
total cholesterol. These findings were replicated in Finn-
Gen, and individuals with SAP had a C index of 0.665 
(95% CI, 0.655–0.674) and individuals without SAP had 
a C index of 0.825 (95% CI, 0.821–0.830). The lower C 
index in individuals with SAP was explained by the lower 
association between established cardiovascular risk fac-
tors, including age, and ACS in these individuals.
Because it is easier to obtain a higher improvement 
in predictive performance (ΔC index) when the base-
line model has a lower prediction performance,28,29 we 
expected the improvement in C index due to PS to be 
higher in individuals with SAP. Nevertheless, the addition 
of PS to measured risk factors increased the C index 
more in individuals without SAP (ΔC index=0.021) than 
Figure 2. Interaction between 
polygenic score (PS) and 80 clinical 
conditions significantly (P<1.23×10−4) 
associated with acute coronary 
syndrome (ACS) after multiple testing 
correction from the UK Biobank.
Red dotted line is the significance 
threshold (P<1.23×10−4). Top 10 
clinical conditions are labeled. There 
was a significant interaction between 
stable angina pectoris (SAP) and PS in 
association with ACS (P=2.87×10−8) 
that was replicated in FinnGen 
(P=1.38×10−6). There was also a 
significant interaction between SAP and 
type 2 diabetes (P=6.01×10−6) in the 
UK Biobank, but this interaction was not 
significant after multiple testing correction 
in FinnGen (P=5.00×10−2).
Figure 3. Hazard ratios for association between polygenic 
score (PS) and acute coronary syndrome (ACS) in individuals 
with and without stable angina pectoris (SAP).
In the UK Biobank, individuals with SAP had a hazard ratio of 1.163 
(95% CI, 1.082–1.251) and individuals without SAP had a hazard 
ratio of 1.531 (95% CI, 1.497–1.565). In FinnGen, individuals 
with SAP had a hazard ratio of 1.247 (95% CI, 1.173–1.326) 
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in individuals with SAP (ΔC index=0.010). In FinnGen, 
PS increased the C index by 0.012 in individuals without 
SAP and by 0.013 in individuals with SAP. Last, we calcu-
lated the net reclassification index (NRI) to evaluate the 
improvement in reclassification when adding PS to the 
baseline prediction performance of measured risk factors 
(Table V in the Data Supplement). Addition of PS signifi-
cantly improved the prediction performance in individuals 
without SAP (categorical NRI=0.116, P<1.00×10−3; con-
tinuous NRI=0.315, P<1.00×10−3) but not in individuals 
with SAP (NRI=0.038, P=0.187; continuous NRI=0.113, 
P=3.41×10−3). Overall, the NRI was higher among indi-
viduals without SAP compared with individuals with SAP.
DISCUSSION
In this study, we performed an unbiased, comprehen-
sive evaluation of the association between diverse cor-
related clinical conditions and ACS across 2 large-scale 
biobanks. Moreover, by exploring the impact of clinical 
conditions on the association between PS and ACS, we 
provided context for the use of PS for prediction of ACS.
First, we found that a large number of clinical condi-
tions were associated with ACS, independent of mea-
sured risk factors. Using clinical conditions to predict risk 
for ACS may be more convenient than using measured 
risk factors because this information is easily accessed 
and obtained from electronic health records and does 
not require in-person visits. In addition to well-estab-
lished clinical risk factors, such as type 2 diabetes, that 
are routinely considered, additional clinical conditions 
that are associated with ACS may be taken into con-
sideration when evaluating risk for ACS. Identification of 
such clinical conditions is critical to provide a compre-
hensive, well-informed assessment of risk for ACS.
Second, by using a hypothesis-free approach across 
80 clinical conditions associated with ACS, we found 
that the association between PS and ACS was consis-
tent across individuals with or without most of these 
clinical conditions. Diagnosis of a clinical condition did 
not change the association between PS and ACS, sug-
gesting that clinical conditions do not impact the utility 
of PS. Previous work has shown that different groups 
of individuals may benefit more from measuring PS than 
other groups. For example, previous work has shown that 
PS was more predictive of ACS among nonsmokers.30 
However, in our study, we generally found that the diag-
nosis of a clinical condition did not affect the association 
between PS and ACS. The only differential association 
that was found in both the UK Biobank and FinnGen 
was a diagnosis of SAP, in which SAP was significantly 
more associated with ACS in individuals without a previ-
ous diagnosis of SAP than in individuals with a previous 
diagnosis of SAP.
There are at least 2 possible explanations for this 
phenomenon. First, progression of ACS may occur with 
or without the presentation of SAP. It is possible that 
individuals who develop ACS with or without prior SAP 
are clinically and genetically distinct. It is widely accepted 
that ACS varies in clinical presentation, and other stud-
ies have explored the significance of a diagnosis of SAP 
before ACS.31–34 For example, other studies have found 
that individuals with prior SAP had more extensive ath-
erosclerosis and a greater prevalence of clinical risk fac-
tors, such as hypertension, than individuals without prior 
SAP who developed ACS.35,36 In another study, myocar-
dial infarction was the most common first clinical pre-
sentation in individuals without prior SAP who developed 
ACS.31 Other studies have also found that individuals with 
prior SAP had a more favorable prognosis compared with 
individuals without prior SAP who developed ACS.35,37 In 
our study, we found a differential association between 
PS and ACS in individuals with and without SAP, further 
suggesting that these individuals may be clinically and 
genetically distinct. Taken together, there may be differ-
ent pathways of progression of ACS that may warrant 
different assessments and interventions.
Second, a diagnosis of SAP may be synonymous 
to a diagnosis of CHD. In a clinical setting, individuals 
with SAP often have already started developing CHD. 
Subsequently, individuals with SAP may already have a 
higher risk for ACS, and PS may not be as informative. 
As a result, PS may lose its prediction performance in 
individuals who have already been diagnosed with SAP. 
This observation is supported by other studies that have 
shown that prediction of secondary CHD events by PS is 
Figure 4. Difference in discrimination for acute coronary 
syndrome (ACS), measured by the Harrell C index.
In the UK Biobank, individuals with stable angina pectoris (SAP) 
had a C index of 0.606 (95% CI, 0.595–0.616) and individuals 
without SAP had a C index of 0.747 (95% CI, 0.743–0.750). 
In FinnGen, individuals with SAP had a C index of 0.665 (95% 
CI, 0.655–0.674) and individuals without SAP had a C index of 
0.825 (95% CI, 0.821–0.830). The lower C index in individuals 
with SAP is explained by the lower association between 
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attenuated compared with that of primary CHD events.38 
Indeed, we found that PS was strongly associated with 
SAP, suggesting that there is a large overlap in the 
genetic basis of SAP and ACS.
An open matter that may explain this phenomenon is 
index event bias. Index event bias may occur in studies 
that select patients based on the occurrence of an index 
event, and as a result, measured risk factors may have 
less of an effect on recurrent events.39–41 In our study, 
SAP may be an index event that decreased the predic-
tion performance of PS in individuals with SAP compared 
with individuals without SAP. In other words, because 
ACS is dependent on multiple factors, such as underly-
ing chronic conditions and measured risk factors, con-
ditioning on a diagnosis of SAP creates a dependence 
between such factors. As a result, individuals with SAP 
do not require the same burden of increased measured 
risk factors and increased PS to develop ACS. As men-
tioned previously, individuals with SAP are more likely to 
have underlying chronic conditions, such as extensive 
atherosclerosis. This may entail that measured risk fac-
tors and PS do not need to have a large association with 
ACS to confer the same risk, due to the presence of such 
underlying chronic conditions. Indeed, our study showed 
that measured risk factors and PS were less associated 
with ACS in individuals with SAP, reflecting other studies 
that have also shown that individuals with SAP often have 
less associated measured risk factors.31 Additionally, we 
found that BMI was the only measured risk factor that 
had a significant, but modest, interaction with PS. Pre-
vious work has similarly examined whether index event 
bias affected the attenuated association of the chromo-
some 9p21 locus and subsequent CHD and found that 
BMI indeed modestly affected this association.42 While 
we excluded individuals with known ACS, our sensitivity 
analyses indicated that index event bias does not solely 
explain the effect size differences for SAP.39,43
A few limitations of this study must be considered. 
First, the definition of ACS and clinical conditions were 
based on diagnostic codes derived from national health 
registries. Underreporting and incorrect use of diagnos-
tic codes in a clinical setting are inherent to this type of 
data. Nevertheless, we obtained similar results in 2 large-
scale biobanks from the United Kingdom and Finland. 
Additional evidence from other studies also supports 
the quality of this type of data.44–46 Future studies are 
needed to fully assess the validity of using registry-based 
clinical conditions across large-scale biobanks from dif-
ferent countries, but our study supports the feasibility of 
cross-nation registry-based analyses. Second, our PS 
represents a snapshot of current research in genetic 
scores. PS is inherently tied to the study used to con-
struct the genetic scores, and as larger genome-wide 
association studies are conducted, genetic scores will 
necessarily improve and become more predictive. There-
fore, our results represent a lower bound of prediction 
performance of PS, and it is likely that additional studies 
that improve genetic scores will improve the prediction 
performance of PS. Third, while our study included indi-
viduals from different ancestry groups, individuals from 
European ancestry comprised the majority of our cohort. 
Whether our findings generalize to non-European ances-
try groups requires further study. This reflects a larger 
problem of the lack of diversity in genetic research and 
global efforts continue to address this problem.47
CONCLUSIONS
Using an unbiased, comprehensive approach, we identi-
fied clinical conditions that were associated with ACS, 
independent of measured risk factors. Overall, we found 
that the association between PS and ACS remained con-
sistent across many clinical conditions, suggesting that 
the utility of PS for prediction of ACS is largely inde-
pendent of previous clinical conditions experienced by 
the patient. Nevertheless, we found one exception: indi-
viduals without SAP had a greater association between 
PS and ACS than individuals with SAP. In conclusion, 
we demonstrated that PS may be more appropriate for 
prediction of ACS among asymptomatic individual than 
symptomatic individuals with clinical suspicion for CHD.
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